Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2021 03:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics förbereder notering på Nasdaq First North Growth Market

STOCKHOLM, SVERIGE 15 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics förbereder en notering på Nasdaq First North Growth Market...
March 15, 2021 03:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics initiates preparations for listing on Nasdaq First North Growth Market

STOCKHOLM, SWEDEN – March 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a listing on Nasdaq First North Growth...
March 10, 2021 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics förbereder kliniskt utvecklingsprogram för sevuparin vid sepsis / septisk chock

STOCKHOLM, SVERIGE 10 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics förbereder ett kliniskt utvecklingsprogram för sin...
March 10, 2021 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics prepares clinical development program of sevuparin in sepsis/septic shock

STOCKHOLM, SWEDEN – March 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics is preparing a clinical development program of its...
March 03, 2021 03:04 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Forendo Pharma tar FOR-6219 vidare till fas 2-studie baserat på positiva fas 1-resultat

STOCKHOLM, SVERIGE 3 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Forendo Pharma framgångsrikt har genomfört ett kliniskt fas 1-program för FOR-6219...
March 03, 2021 03:04 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data

STOCKHOLM, SWEDEN – March 3, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company, Forendo Pharma, has successfully completed a Phase 1 program for...
March 02, 2021 11:02 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag OssDsign genomför en fullt garanterad företrädesemission och lanserar ny bolagsstrategi

STOCKHOLM, SVERIGE 2 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen i portföljbolaget OssDsign har beslutat att genomföra en fullt garanterad...
March 02, 2021 11:02 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company OssDsign announces a fully guaranteed rights issue and launches new corporate strategy

STOCKHOLM, SWEDEN – March 2, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign has decided to carry out a fully guaranteed rights issue of...
March 01, 2021 07:13 ET | Source: Karolinska Development AB (publ)

Karolinska Development utser Per Aniansson till ny finansdirektör och Investment Director

STOCKHOLM, SVERIGE 1 mars 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att Per Aniansson har utsetts till ny finansdirektör och Investment Director. Han har omfattande...
March 01, 2021 07:13 ET | Source: Karolinska Development AB (publ)

Karolinska Development appoints Per Aniansson as CFO and Investment Director

STOCKHOLM, SWEDEN – March 1, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that Per Aniansson has been appointed as new CFO and Investment Director. He has extensive...